ASCO-GI 2019: Pankreaskarzinom

Während bei vielen Tumorentitäten große Fortschritte in der Behandlung zu berichten sind, bleibt das Pankreaskarzinom ein Tumor mit einer schlechten Prognose und wenigen Therapieoptionen. Beim Gastrointestinal Cancers Symposium (ASCO­GI) wurde eine Sitzung der frühen Detektion, der Sequenztherapie resektabler Tumoren und den Therapien der Zukunft beim Pankreaskarzinom gewidmet.

• Literatur

• 1 Sadot E. et al. Tumor-associated neutrophils and malignant progression in intraductal papillary mucinous neoplasms: An opportunity for identification of high-risk disease.. Ann Surg 2015; 262: 1102-1107.
• 2 Al Efishat M. et al. Multi-institutional validation study of pancreatic cyst fluid protein analysis for prediction of high-risk intraductal papillary mucinous neoplasms of the pancreas.. Ann Surg 2018; 268: 340-347.
• 3 Al Efishat M. et al. Progression patterns in the remnant pancreas after resection of non-invasive or micro-invasive intraductal papillary mucinous neoplasms (IPMN).. Ann Surg Oncol 2018; 25: 1752-1759.
• 4 Ryan DP. et al. Pancreatic adenocarcinoma.. N Engl J Med 2014; 371: 1039-1049.
• 5 Ghaneh P. et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma.. Ann Surg 2019; 269: 520-529
• 6 Jang JY. et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabin versus upfront surgery in patients with borderline resectabie pancreatic cancer: A prospective, randomized, open-label, multicenter phase ⅔ trial.. Ann Surg 2018; 268: 215-222
• 7 Van Tienhoven. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.. ASCO 2018, Abstract LBA4002
• 8 Murphy JE. et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial.. JAMA Oncol 2018; 4: 963-969
• 9 O’Reilly EM. et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.. Cancer 2018; 124: 1374-1382